Hikma Pharmaceuticals PLC (HIK) - Net Assets

Latest as of June 2025: GBX2.55 Billion GBX ≈ $310.38K USD

Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has net assets worth GBX2.55 Billion GBX (≈ $310.38K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX5.55 Billion ≈ $675.76K USD) and total liabilities (GBX3.00 Billion ≈ $365.38K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check HIK tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX2.55 Billion
% of Total Assets 45.93%
Annual Growth Rate 19.27%
5-Year Change 8.05%
10-Year Change 71.67%
Growth Volatility 36.99

Hikma Pharmaceuticals PLC - Net Assets Trend (2002–2024)

This chart illustrates how Hikma Pharmaceuticals PLC's net assets have evolved over time, based on quarterly financial data. See HIK defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Hikma Pharmaceuticals PLC (2002–2024)

The table below shows the annual net assets of Hikma Pharmaceuticals PLC from 2002 to 2024. For live valuation and market cap data, see HIK stock market capitalisation.

Year Net Assets Change
2024-12-31 GBX2.32 Billion
≈ $282.40K		 +5.07%
2023-12-31 GBX2.21 Billion
≈ $268.77K		 +2.84%
2022-12-31 GBX2.15 Billion
≈ $261.35K		 -12.93%
2021-12-31 GBX2.47 Billion
≈ $300.16K		 +14.85%
2020-12-31 GBX2.15 Billion
≈ $261.35K		 +0.89%
2019-12-31 GBX2.13 Billion
≈ $259.04K		 +25.46%
2018-12-31 GBX1.70 Billion
≈ $206.48K		 +11.06%
2017-12-31 GBX1.53 Billion
≈ $185.91K		 -36.62%
2016-12-31 GBX2.41 Billion
≈ $293.35K		 +78.33%
2015-12-31 GBX1.35 Billion
≈ $164.50K		 +11.18%
2014-12-31 GBX1.22 Billion
≈ $147.95K		 +17.60%
2013-12-31 GBX1.03 Billion
≈ $125.81K		 +21.96%
2012-12-31 GBX847.85 Million
≈ $103.16K		 +6.16%
2011-12-31 GBX798.63 Million
≈ $97.17K		 +6.44%
2010-12-31 GBX750.30 Million
≈ $91.29K		 +9.81%
2009-12-31 GBX683.26 Million
≈ $83.13K		 +12.19%
2008-12-31 GBX609.00 Million
≈ $74.10K		 +43.41%
2007-12-31 GBX424.66 Million
≈ $51.67K		 +21.40%
2006-12-31 GBX349.80 Million
≈ $42.56K		 +21.68%
2005-12-31 GBX287.48 Million
≈ $34.98K		 +98.02%
2004-12-31 GBX145.18 Million
≈ $17.66K		 +140.07%
2003-12-31 GBX60.47 Million
≈ $7.36K		 +25.91%
2002-12-31 GBX48.03 Million
≈ $5.84K		 --

Equity Component Analysis

This analysis shows how different components contribute to Hikma Pharmaceuticals PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 236200000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings GBX2.36 Billion 102.25%
Common Stock GBX40.00 Million 1.73%
Total Equity GBX2.31 Billion 100.00%

Hikma Pharmaceuticals PLC Competitors by Market Cap

The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their market capitalization.

Company Market Cap
BJC Heavy Industries Public Company Limited
BK:BJCHI
 $39.53 Million
Nuintek Co.Ltd
KQ:012340
 $39.55 Million
BG Staffing Inc
NYSE:BGSF
 $39.55 Million
Swiss Water Decaffeinated Coffee Inc
TO:SWP
 $39.55 Million
Fiyta Holdings Ltd
SHE:200026
 $39.53 Million
SCI Information Service Inc
KQ:036120
 $39.49 Million
KebNi AB (publ)
ST:KEBNI-B
 $39.47 Million
Total Soft Bank Ltd
KQ:045340
 $39.47 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hikma Pharmaceuticals PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,198,000,000 to 2,310,000,000, a change of 112,000,000 (5.1%).
  • Net income of 359,000,000 contributed positively to equity growth.
  • Dividend payments of 175,000,000 reduced retained earnings.
  • Other comprehensive income increased equity by 282,000,000.
  • Other factors decreased equity by 316,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX359.00 Million +15.54%
Dividends Paid GBX175.00 Million -7.58%
Other Comprehensive Income GBX282.00 Million +12.21%
Other Changes GBX-316.00 Million -13.68%
Total Change GBX- 5.10%

Book Value vs Market Value Analysis

This analysis compares Hikma Pharmaceuticals PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 141.93x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 5116.47x to 141.93x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 GBX0.29 GBX1467.00 x
2003-12-31 GBX0.36 GBX1467.00 x
2004-12-31 GBX0.86 GBX1467.00 x
2005-12-31 GBX1.83 GBX1467.00 x
2006-12-31 GBX1.96 GBX1467.00 x
2007-12-31 GBX2.37 GBX1467.00 x
2008-12-31 GBX3.12 GBX1467.00 x
2009-12-31 GBX3.49 GBX1467.00 x
2010-12-31 GBX3.78 GBX1467.00 x
2011-12-31 GBX3.93 GBX1467.00 x
2012-12-31 GBX4.21 GBX1467.00 x
2013-12-31 GBX5.14 GBX1467.00 x
2014-12-31 GBX5.99 GBX1467.00 x
2015-12-31 GBX6.65 GBX1467.00 x
2016-12-31 GBX10.24 GBX1467.00 x
2017-12-31 GBX6.31 GBX1467.00 x
2018-12-31 GBX6.96 GBX1467.00 x
2019-12-31 GBX8.71 GBX1467.00 x
2020-12-31 GBX8.97 GBX1467.00 x
2021-12-31 GBX10.53 GBX1467.00 x
2022-12-31 GBX9.49 GBX1467.00 x
2023-12-31 GBX9.88 GBX1467.00 x
2024-12-31 GBX10.34 GBX1467.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hikma Pharmaceuticals PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 15.54%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 11.48%
  • • Asset Turnover: 0.61x
  • • Equity Multiplier: 2.22x
  • Recent ROE (15.54%) is above the historical average (13.22%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 21.99% 12.28% 0.90x 1.99x GBX5.72 Million
2003 29.28% 16.73% 0.89x 1.96x GBX11.58 Million
2004 26.29% 17.64% 0.86x 1.73x GBX23.21 Million
2005 15.45% 16.73% 0.66x 1.40x GBX15.48 Million
2006 15.80% 17.20% 0.65x 1.42x GBX20.02 Million
2007 14.95% 13.94% 0.50x 2.14x GBX20.73 Million
2008 9.47% 9.84% 0.60x 1.60x GBX-3.20 Million
2009 11.49% 12.20% 0.62x 1.51x GBX10.09 Million
2010 13.29% 13.52% 0.66x 1.50x GBX24.46 Million
2011 10.32% 8.73% 0.58x 2.03x GBX2.45 Million
2012 12.01% 9.02% 0.64x 2.08x GBX16.73 Million
2013 20.85% 15.53% 0.71x 1.90x GBX110.30 Million
2014 23.22% 18.67% 0.66x 1.88x GBX158.30 Million
2015 18.85% 17.50% 0.55x 1.94x GBX118.30 Million
2016 6.47% 7.95% 0.45x 1.82x GBX-84.60 Million
2017 -55.68% -43.54% 0.57x 2.24x GBX-994.40 Million
2018 16.74% 13.62% 0.59x 2.08x GBX113.50 Million
2019 22.96% 22.02% 0.56x 1.86x GBX274.30 Million
2020 20.19% 18.41% 0.57x 1.94x GBX217.50 Million
2021 17.16% 16.49% 0.58x 1.78x GBX175.70 Million
2022 8.81% 7.47% 0.56x 2.09x GBX-25.50 Million
2023 8.64% 6.61% 0.61x 2.13x GBX-29.80 Million
2024 15.54% 11.48% 0.61x 2.22x GBX128.00 Million

Industry Comparison

This section compares Hikma Pharmaceuticals PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,983,613,937
  • Average return on equity (ROE) among peers: -73.85%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hikma Pharmaceuticals PLC (HIK) GBX2.55 Billion 21.99% 1.18x $39.53 Million
Allergy Therapeutics (AGY) $20.08 Million -10.91% 0.33x $5.60 Million
Animalcare Group Plc (ANCR) $3.80 Million 0.00% 0.57x $2.78 Million
Alliance Pharma plc (APH) $70.78 Million 11.85% 0.52x $4.26 Million
Celadon Pharmaceuticals PLC (CEL) $3.18 Million -224.46% 1.90x $112.25K
Chill Brands Group PLC (CHLL) $878.67K -488.00% 5.99x $174.97K
Eco Animal Health Group Plc (EAH) $58.25 Million 3.81% 0.20x $750.93K
HUTCHMED China Ltd (HCM) $1.25 Billion 36.57% 0.40x $16.32 Million
Haleon PLC (HLN) $16.46 Billion 6.44% 1.12x $361.16 Million
Indivior PLC (INDV) $-11.00 Million 0.00% 0.00x $18.79 Million

About Hikma Pharmaceuticals PLC

LSE:HIK UK Drug Manufacturers - Specialty & Generic
Market Cap
$39.53 Million
GBX324.87 Billion GBX
Market Cap Rank
#22821 Global
#184 in UK
Share Price
GBX1467.00
Change (1 day)
+0.00%
52-Week Range
GBX1191.00 - GBX2070.00
All Time High
GBX2408.28
Categories
Companies in UK Drug Manufacturers - Specialty & Generic
About

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more